Financial Performance - Total revenue for Q1 2019 was ¥157,516,005.82, representing a 13.02% increase compared to ¥139,373,501.83 in the same period last year[8] - Net profit attributable to shareholders was ¥28,988,539.43, up 19.17% from ¥24,326,370.73 year-on-year[8] - Basic earnings per share decreased by 7.14% to ¥0.13 from ¥0.14 in the same period last year[8] - Operating profit for the same period was CNY 31.93 million, up 10.17% year-on-year[20] - The company achieved operating revenue of 157.52 million yuan and a net profit attributable to the parent company of 28.99 million yuan, completing 17.50% of the annual target[31] - The company's net profit for Q1 2019 was CNY 27,681,552.42, reflecting a growth from CNY 29,235,969.16 in Q1 2018[75] - The net profit for Q1 2019 reached CNY 27,906,068.43, up from CNY 25,800,726.43, representing an increase of approximately 8.1% year-over-year[78] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,344,188,612.93, a 1.78% increase from ¥2,303,099,575.06 at the end of the previous year[8] - Current liabilities totaled CNY 981,434,681.19, a slight decrease from CNY 995,790,181.92 in the previous quarter[69] - Long-term borrowings rose by 158.29% to CNY 45.53 million, mainly due to increased mortgage loans from subsidiaries[19] - The total equity attributable to shareholders increased to CNY 1,303,660,985.42 from CNY 1,274,626,554.01, reflecting a growth of 2.3%[71] Cash Flow - Net cash flow from operating activities improved to -¥29,671,202.63, a 26.73% reduction in losses compared to -¥40,493,779.44 in the previous year[8] - The net cash flow from operating activities for the first quarter was ¥23,885,438.28, a significant improvement compared to the previous year's negative cash flow of -¥181,431,977.63[88] - Total cash inflow from operating activities reached ¥111,862,588.75, up from ¥72,564,351.24 in the same period last year[88] - Cash outflow from operating activities decreased to ¥87,977,150.47 from ¥253,996,328.87 year-on-year[88] Research and Development - The total R&D expenditure for the reporting period was 7.6963 million yuan, accounting for 4.89% of the company's revenue[23] - The remote pathology digital consultation project has completed the project initiation, development, configuration, and testing phases, addressing key technical issues related to image quality and selection errors[23] - The company is focused on research and development of new products and technologies to enhance its market position[40] - Research and development expenses increased to CNY 3,446,666.02, up from CNY 2,593,363.63, reflecting a growth of 33% year-over-year[80] Market and Strategic Plans - The company plans to achieve an annual revenue target of no less than CNY 900 million and a profit target of no less than CNY 180 million for 2019[22] - The increase in revenue was driven by the expansion of the PVP product market and sales of the Euriz product, which contributed over CNY 6.75 million in profit[21] - The company is actively pursuing market expansion and strategic partnerships as part of its growth strategy[40] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,418[11] - The top shareholder, Wang Donghu, holds 20.00% of the shares, totaling 43,586,144 shares[11] - No repurchase transactions were conducted by the top 10 shareholders during the reporting period[12] Compliance and Governance - The company is committed to sharing its research outcomes with the academic community to foster collaboration and innovation in the field[27] - The controlling shareholders have signed an agreement to maintain consistent voting rights and proposals during shareholder meetings[50] - The company has established a performance compensation mechanism to address any shortfalls in profit commitments[46] Investment and Funding - The total amount of raised funds is CNY 17,432.5 million, with CNY 0.08 million invested in the current quarter[59] - Cumulative investment of raised funds amounts to CNY 16,777.18 million, representing 96.23% of the total commitment[59] - The cervical cancer screening project has achieved a cumulative investment of CNY 3,659.53 million, reaching 100.26% of its planned investment[59]

博爱新开源医疗科技集团股份有限公司 2018 年第三季度报告全文 博爱新开源医疗科技集团股份有限公司 2018 年第三季度报告 2018 年 10 月 1 博爱新开源医疗科技集团股份有限公司 2018 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人方华生、主管会计工作负责人刘爱民及会计机构负责人(会计主 管人员)李春平声明：保证季度报告中财务报表的真实、准确、完整。 2 博爱新开源医疗科技集团股份有限公司 2018 年第三季度报告全文 第二节 公司基本情况 3 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增 | | --- | --- | --- | --- | --- | | | | | | 减 | | 总资产（元） | 2,162,320,825.62 | | 1,958,639,629.26 | 10.40% | | 归属于上市公 ...

博爱新开源医疗科技集团股份有限公司 2018 年半年度报告全文 博爱新开源医疗科技集团股份有限公司 2018 年半年度报告 2018 年 08 月 博爱新开源医疗科技集团股份有限公司 2018 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人方华生、主管会计工作负责人刘爱民及会计机构负责人(会计主 管人员)李春平声明：保证本半年度报告中财务报告的真实、准确、完整。 1 博爱新开源医疗科技集团股份有限公司 2018 年半年度报告全文 所有董事均已出席了审议本报告的董事会会议。 1、安全生产的风险 公司主要从事 PVP 系列产品的研发、生产和销售。产品原料中含有乙炔、 乙烯基甲醚等化工原料，乙炔具有弱麻醉作用，高浓度吸入可引起单纯窒息， 遇明火易发生爆炸。当混有磷化氢、硫化氢时，毒性增大，职业性接触毒物危 害程度分级为Ⅲ级。乙烯基甲醚属于易燃物质，与空气混合能形成爆炸性混合 物，遇明火、高热极易燃烧爆炸。 公司自成立以来，就一直严格遵守国家相关安全生 ...

博爱新开源医疗科技集团股份有限公司 2018 年第一季度报告全文 博爱新开源医疗科技集团股份有限公司 2018 年第一季度报告 2018-059 2018 年 04 月 博爱新开源医疗科技集团股份有限公司 2018 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人方华生、主管会计工作负责人刘爱民及会计机构负责人(会计主 管人员)李春平声明：保证季度报告中财务报表的真实、准确、完整。 1 博爱新开源医疗科技集团股份有限公司 2018 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 139,373,501.83 | 105,999,434.10 | 31.49% | | 归属于上市公司股东的净利润（ ...

Financial Performance - The company's operating revenue for 2017 was ¥488,581,464.45, representing a 21.96% increase compared to ¥400,618,888.54 in 2016[28]. - The net profit attributable to shareholders for 2017 was ¥92,823,189.13, a 15.97% increase from ¥80,039,829.52 in 2016[28]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥90,563,694.41, up 15.66% from ¥78,302,419.72 in 2016[28]. - The net cash flow from operating activities decreased by 58.58% to ¥47,279,359.30 from ¥114,144,488.79 in 2016[28]. - The total assets at the end of 2017 were ¥1,958,639,629.26, a 49.53% increase from ¥1,309,901,362.67 at the end of 2016[28]. - The net assets attributable to shareholders at the end of 2017 were ¥1,301,859,620.31, a 6.20% increase from ¥1,225,846,022.24 at the end of 2016[28]. - The basic earnings per share for 2017 was ¥0.55, an increase of 17.02% from ¥0.47 in 2016[28]. - The diluted earnings per share for 2017 was also ¥0.55, reflecting the same growth of 17.02% from ¥0.47 in 2016[28]. - The weighted average return on equity for 2017 was 7.36%, up from 6.70% in 2016[28]. - The quarterly operating revenue for Q4 2017 was ¥140,304,436.40, showing a strong performance compared to previous quarters[30]. Investment and R&D - The company has increased its capitalized R&D expenditures, contributing to enhanced research capabilities and profitability[41]. - Investment in R&D has increased by 25%, focusing on the development of innovative medical devices and technologies to enhance service offerings[46]. - The company has filed for 10 new patents in 2017, indicating a strong commitment to innovation and technological advancement in the healthcare sector[46]. - The company’s R&D investment totaled ¥32,755,279.63, accounting for 6.70% of its revenue[84]. - The number of R&D personnel increased to 196 in 2017, accounting for 26.56% of the total workforce, up from 20.82% in 2016[93]. Market Expansion and Strategy - The company is actively expanding into overseas markets and is involved in significant asset restructuring, which is subject to approval from the board and regulatory authorities[14]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[46]. - The company aims to expand its market reach through the introduction of innovative products and technologies in the healthcare sector[44]. - The company has outlined a positive outlook for 2018, projecting a revenue growth of 10-15% driven by new product launches and market expansion efforts[46]. - The company is focusing on expanding its dual-platform strategy in specialty chemicals and healthcare services to enhance growth potential[37]. Compliance and Risk Management - The company is closely monitoring changes in national policies affecting the pharmaceutical industry to ensure compliance and adapt internal management practices accordingly[8]. - The company has established a comprehensive safety production management system to mitigate risks associated with safety management and equipment[5]. - The company acknowledges risks related to new product development in the in vitro diagnostics industry, which involves long cycles and high technical challenges[9]. - The company is committed to improving its investment decision-making and management capabilities to address risks associated with overseas investments[13]. - The company emphasizes the importance of high-quality technical talent in the high-tech service industry, highlighting the need for effective incentive mechanisms to retain and attract talent[12]. Environmental and Safety Initiatives - The company is enhancing its environmental protection efforts in response to stricter regulations, including optimizing energy systems and adjusting product structures[7]. - The company has not experienced any major safety production accidents during the reporting period, despite existing risks associated with chemical materials used in production[5]. - The company implemented a comprehensive EHS system to ensure strict environmental and safety management[62]. - The total pollution discharge limits for the company are set at 12.958 tons/year for chemical oxygen demand and 43.93 tons/year for sulfur dioxide[54]. Shareholder and Profit Distribution - The company reported a total cash dividend for the year 2017 of RMB 16,973,226.10, which is 100% of the total profit distribution[136]. - The cash dividend per share for 2017 is RMB 1.00, with a base of 169,732,261 shares[137]. - The cash dividend payout ratio for 2017 is 18.29% of the net profit attributable to ordinary shareholders, which is RMB 92,823,189.13[138]. - The company has consistently maintained a cash dividend distribution policy over the past three years[137]. - The company’s distributable profit for the year is RMB 182,817,331.83[136]. Subsidiaries and Acquisitions - The subsidiary He'er Medical reported operating revenue of ¥55,788,266.22 and net profit of ¥24,868,391.44[60]. - Sanji Biological achieved operating revenue of ¥61,270,187.75 and net profit of ¥16,303,216.56[60]. - Jingneng Biological generated operating revenue of ¥65,746,018.59 with a net profit of ¥8,243,950.29[60]. - The company has completed acquisitions in the in vitro diagnostics sector, entering the fields of early cancer diagnosis and molecular diagnostics[120]. - The company plans to acquire BioVision to enhance its market competitiveness in the healthcare sector, leveraging synergies in products, channels, R&D, and management[121]. Future Outlook - The company has outlined a positive outlook for the next fiscal year, projecting a revenue growth of 25%[48]. - The company aims to achieve a revenue of no less than 700 million RMB and a profit of no less than 120 million RMB in 2018[127]. - The company plans to focus on sales, targeting a sales figure of 350 million RMB for its main products in 2018, while also expanding its market presence domestically and internationally[127]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for potential mergers[146]. - The company is committed to maintaining a 20% profit margin while expanding its operations[148].

博爱新开源制药股份有限公司 2017 年第三季度报告全文 博爱新开源制药股份有限公司 2017 年第三季度报告 2017 年 10 月 博爱新开源制药股份有限公司 2017 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人方华生、主管会计工作负责人刘爱民及会计机构负责人(会计主 管人员)李春平声明：保证季度报告中财务报表的真实、准确、完整。 1 博爱新开源制药股份有限公司 2017 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 1,563,495,853.72 | 1,309,901,362.67 | | 19.36% | | 归属于上市公司股东的净资产 （元） | 1,284 ...

Financial Performance - Total revenue for the first half of 2017 was CNY 231,015,866.97, representing a 14.09% increase compared to CNY 202,492,290.03 in the same period last year[24]. - Net profit attributable to shareholders was CNY 51,250,931.09, up 20.20% from CNY 42,637,196.31 year-on-year[24]. - Net profit after deducting non-recurring gains and losses was CNY 50,134,039.60, reflecting a 19.25% increase from CNY 42,041,643.27 in the previous year[24]. - Basic earnings per share increased to CNY 0.30, a 20.00% rise from CNY 0.25 in the same period last year[24]. - The overall gross margin for the first half of 2017 was reported at 45%, indicating strong operational efficiency and cost management[38]. - Operating profit reached CNY 58.58 million, reflecting an 18.63% growth compared to the previous year[52]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion CNY for the first half of 2017, representing a 20% growth compared to the same period last year[45]. - The company provided a positive outlook for the second half of 2017, projecting a revenue growth of 25% year-over-year[46]. Research and Development - The company reported a significant focus on the R&D, production, and sales of PVP series products, with a commitment to safety and compliance with national regulations[5]. - Research and development efforts are being intensified, with an investment of approximately 10 million RMB allocated for new drug formulations and technologies in 2017[38]. - The company is focusing on the development of gene sequencing reagents and personalized medication solutions as core business areas[79]. - The company is committed to technological research and development, which is crucial for maintaining competitive advantage in the pharmaceutical industry[40]. - The company has made significant advancements in the development of new technologies related to drug gene testing systems[43]. Market Expansion and Strategy - The company is committed to expanding its market presence and enhancing its R&D capabilities, focusing on consumer specialty chemicals and health care services[31]. - The company is focusing on expanding its market presence through new product development and strategic partnerships, aiming for a 15% increase in market share by the end of 2018[38]. - The company is exploring market expansion opportunities in Southeast Asia, targeting a 20% market share within the next two years[102]. - A strategic acquisition is planned, with the company aiming to acquire a competitor to enhance its product portfolio and market presence[103]. - The company is actively pursuing research and development in the field of cancer gene targeting software[43]. Environmental and Compliance Efforts - Environmental protection efforts have intensified since the implementation of the new Environmental Protection Law in January 2015, leading to increased investment in pollution control measures[7]. - The company emphasized safety and environmental protection, ensuring stable operation of production facilities[53]. - Environmental compliance measures were highlighted, with a commitment to reducing chemical emissions by 15% over the next three years[46]. - The company is not classified as a key pollutant discharge unit by environmental protection authorities[125]. Asset Management and Financial Health - Total assets at the end of the reporting period were CNY 1,370,076,543.85, a 4.59% increase from CNY 1,309,901,362.67 at the end of the previous year[24]. - The company has a robust asset base, with fixed asset depreciation amounting to approximately ¥15.28 million during the reporting period[34]. - The company reported a significant reduction in financial expenses, decreasing by 88.22% to ¥416,140.91 from ¥3,533,692.42, primarily due to lower interest expenses[58]. - The company’s cash and cash equivalents decreased to CNY 34,867,043.98 from CNY 57,530,729.92, a decline of approximately 39.4%[157]. Shareholder and Equity Information - The company has decided not to distribute cash dividends or issue bonus shares during this reporting period[10]. - The company reported a shareholding of 88% that cannot be transferred within 12 months from the date of listing, with 12% unlocking after 36 months[95]. - The company has a normal performance of share lock-up agreements, with the next unlocking date set for September 29, 2019[97]. - The total number of shareholders at the end of the reporting period is 14,052[137]. Subsidiary Performance - The subsidiary Wuhan He'er Medical Technology Development Co., Ltd. reported total assets of CNY 147.65 million and a net profit of CNY 11.95 million[79]. - The subsidiary Changsha Sanji Biological Technology Co., Ltd. reported total assets of CNY 125.98 million and a net profit of CNY 7.45 million[79]. - The company has a 40% stake in Contract New Source Pharmaceutical Co., Ltd., which focuses on PVP products and related pharmaceuticals[83]. Future Guidance - Future guidance indicates an expected revenue growth of 25% year-over-year for the next fiscal year, driven by new product launches and market expansion[38]. - The company has outlined future performance guidance, indicating expectations for revenue growth and market share expansion in the upcoming quarters[40]. - The company plans to enhance its distribution network, targeting a 20% increase in the number of retail partners by the end of 2017[38].

博爱新开源制药股份有限公司 2017 年第一季度报告全文 博爱新开源制药股份有限公司 2017 年第一季度报告 2017-026 2017 年 04 月 博爱新开源制药股份有限公司 2017 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人方华生、主管会计工作负责人刘爱民及会计机构负责人(会计主 管人员)李春平声明：保证季度报告中财务报表的真实、准确、完整。 2 博爱新开源制药股份有限公司 2017 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 105,999,434.10 | 92,348,591.63 | 14.78% | | 归属于上市公司股东的净利润（元） ...

Company Growth and Market Expansion - The company has maintained a fast growth rate and is actively expanding into overseas markets, focusing on improving investment decision-making and management capabilities to mitigate risks associated with foreign investments [13]. - The company aims to expand its market presence in Europe and North America, with a target of entering at least three new countries by the end of 2017 [19]. - The company is actively pursuing partnerships with international firms to leverage advanced technologies and expand its global footprint [19]. - The company is focusing on the dual-platform strategy of "specialty chemicals" and "healthcare services" to drive future growth [135]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years [56]. Financial Performance - Boai NKY Pharmaceuticals reported a total revenue of RMB 1.2 billion for the year 2016, representing a year-on-year increase of 15% [18]. - The company achieved a net profit of RMB 300 million in 2016, which is a 20% increase compared to the previous year [18]. - The company has set a performance guidance for 2017, projecting a revenue growth of 18% and a net profit increase of 22% [19]. - The company reported a significant increase in revenue, reaching 1.5 billion RMB, representing a 20% year-over-year growth [49]. - The company provided guidance for the next fiscal year, projecting a revenue growth of 25% to 1.875 billion RMB [49]. Research and Development - The company is investing RMB 50 million in R&D for new technologies, focusing on molecular diagnostics and gene sequencing [19]. - The company has a strong focus on research and development, with several patents related to drug formulation and diagnostic reagents [52]. - The company has made significant advancements in gene detection technologies, with patents for various detection kits and methods [52]. - The company is committed to integrating advanced medical technologies to strengthen its core competitiveness and become a trusted partner globally [37]. - The company has established a technology R&D center and a polymer application research institute to track global technology trends and meet customer needs [40]. Product Development and Innovation - The company plans to launch two new products in the next fiscal year, targeting a market share increase of 10% in the pharmaceutical sector [19]. - New product launches included three innovative dental care products, expected to contribute an additional 200 million RMB in revenue [49]. - The company has developed multiple innovative devices, including a liquid flow meter and a liquid filtration machine, enhancing its product offerings [50]. - The company has established a detection system for plasma Septin9 gene methylation, achieving early screening for colorectal cancer [89]. - The company is developing gene sequencing test kits, with products obtaining medical device production licenses and entering large-scale production [88]. Safety and Compliance - The company has not experienced any major safety production accidents during the reporting period, despite existing risks related to safety management and operational practices [6]. - The company has established a comprehensive safety management system and has invested in safety training to minimize risks associated with its chemical production processes [6]. - The company has committed to strict safety and environmental management practices, enhancing employee training and accident hazard inspections [144]. - The company has established a comprehensive EHS (Environment, Health, and Safety) system to ensure stable operations and compliance with environmental regulations [144]. - The company is committed to promoting safety and environmental awareness to ensure sustainable development [143]. Acquisitions and Strategic Partnerships - A strategic acquisition of a smaller biotech firm is under consideration, which could enhance the company's product portfolio and market reach [19]. - The company has made strategic acquisitions to enhance its product offerings and market position, including the merger with Shanghai Qianji Medical Testing [39]. - The company has acquired a 73.8% stake in Suzhou Dongsheng Industrial Instrument Co., enhancing its capabilities in PCR instrument production and services [36]. - The company is involved in a major asset restructuring plan, with the assets involved accounting for over 50% of the total assets as per the latest audited financial report [190]. - The company is participating in a national key research project in collaboration with several institutions, enhancing its capabilities in precision medicine [188]. Talent Management and Organizational Development - The company emphasizes the importance of retaining and attracting high-quality technical talent to maintain its innovation and development capabilities in the technology-intensive in vitro diagnostics industry [12]. - The company focused on talent acquisition and retention, implementing a long-term incentive mechanism to align employee performance with corporate goals [69]. - The company aims to build a high-quality talent pool through training and an improved performance evaluation system to support its strategic goals [142]. - The R&D team constitutes 10% of the company's workforce, with multiple patented technologies that fill domestic gaps, including PVME/MA copolymer which has reached international leading levels [40]. - The number of R&D personnel increased to 142 in 2016, accounting for 20.82% of the total workforce [96]. Shareholder and Dividend Policies - The profit distribution plan approved by the board includes a cash dividend of 1.00 yuan per 10 shares (before tax) based on a total of 170,482,422 shares, with no bonus shares issued [13]. - The cash dividend represented 21.30% of the net profit attributable to the company's ordinary shareholders for 2016, which was RMB 80,039,829.52 [152]. - The company has maintained a consistent cash dividend policy over the past three years, with cash dividends of RMB 17,048,242.20 in both 2015 and 2016 [150]. - The company has a commitment to maintain a minimum cash dividend ratio of 20% during significant capital expenditure phases [149]. - The company has established a timeline for the release of locked shares, with specific percentages released at designated intervals [156]. Market Challenges and Competition - The high-end PVP series products have a promising market outlook with high gross margins, but the company faces increasing competition as more players enter this segment [9]. - The company’s high-end PVP products are expected to face intensified competition, particularly in the low-end market where product homogeneity is increasing [9]. - The company aimed for a total sales revenue of no less than RMB 420 million and a profit of no less than RMB 90 million for 2016, but did not meet these targets due to market fluctuations and intensified competition [144]. - The company continues to focus on the production and R&D of PVP series products and has not experienced significant changes in its main business operations [34]. - The company has established collaborations with multiple clinical and genetic experts to enhance the effectiveness of its genetic testing projects [91].

博爱新开源制药股份有限公司 2016 年第三季度报告全文 2016 年第三季度报告 2016 年 10 月 1 博爱新开源制药股份有限公司 2016 年第三季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资 料不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人方华生、主管会计工作负责人刘爱民及会计机构负责人(会计主 管人员)李春平声明：保证季度报告中财务报告的真实、完整。 2 博爱新开源制药股份有限公司 2016 年第三季度报告全文 博爱新开源制药股份有限公司 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增减 | | | --- | --- | --- | --- | --- | | 总资产（元） | 1,297,962,318.72 | 1,235,973,627.53 | | 5.02% | | 归属于上市 ...